Literature DB >> 10880402

Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas.

C Washington1, F Dalbègue, F Abreo, J K Taubenberger, J H Lichy.   

Abstract

Loss of heterozygosity (LOH), a genetic change frequently detected in cancer, can also occur in benign epithelial foci in the breast. To characterize LOH in benign breast tissue, 32 cases containing the various components of fibrocystic change in the absence of malignancy were studied. Microdissected foci of ductal hyperplasia, apocrine metaplasia, sclerosing adenosis, and morphologically normal terminal duct lobular units (TDLUs) were analyzed for LOH at 14 polymorphic loci representing seven chromosomal arms. LOH was detected in 22% of normal TDLUs (6/27), 17% of adenosis (4/23), 19% of hyperplasia (4/21), and 53% of apocrine metaplasia (10/19) specimens. Because of the high percentage of LOH in apocrine metaplasia in nonneoplastic specimens, the genetic relationship between apocrine metaplasia and cancer was studied in a panel of breast cancer cases. Of 14 examples of apocrine metaplasia adjacent to a carcinoma, seven were found to have LOH with at least one marker. In all seven cases, the tumor and apocrine metaplasia shared LOH at one or more markers. The results demonstrate that LOH occurs frequently in the components of fibrocystic change as well as in normal TDLUs and suggest that foci of apocrine metaplasia can share a genetically altered precursor cell with an associated carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880402      PMCID: PMC1850200          DOI: 10.1016/S0002-9440(10)64543-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years.

Authors:  P P Rosen; C Kosloff; P H Lieberman; F Adair; D W Braun
Journal:  Am J Surg Pathol       Date:  1978-09       Impact factor: 6.394

Review 2.  The genetics of sporadic breast cancer.

Authors:  A J Brenner; C M Aldaz
Journal:  Prog Clin Biol Res       Date:  1997

3.  Lobular carcinoma in situ of the breast. Long-term followup.

Authors:  J E Wheeler; H T Enterline; J M Roseman; J P Tomasulo; C H McIlvaine; W T Fitts; J Kirshenbaum
Journal:  Cancer       Date:  1974-09       Impact factor: 6.860

4.  Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer.

Authors:  D M Euhus; A Maitra; I I Wistuba; A Alberts; J Albores-Saavedra; A F Gazdar
Journal:  J Surg Res       Date:  1999-05-01       Impact factor: 2.192

Review 5.  Somatic mutations and human breast cancer. A status report.

Authors:  R Callahan; C S Cropp; G R Merlo; D S Liscia; A P Cappa; R Lidereau
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

6.  Prognostic significance of benign proliferative breast disease.

Authors:  C A Bodian; K H Perzin; R Lattes; P Hoffmann; T G Abernathy
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

7.  Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p.

Authors:  M H Jones; K Yamakawa; Y Nakamura
Journal:  Hum Mol Genet       Date:  1992-05       Impact factor: 6.150

8.  Heterogeneity for allelic loss in human breast cancer.

Authors:  L C Chen; W Kurisu; B M Ljung; E S Goldman; D Moore; H S Smith
Journal:  J Natl Cancer Inst       Date:  1992-04-01       Impact factor: 13.506

9.  Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.

Authors:  A J Brenner; C M Aldaz
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

10.  Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease.

Authors:  D L Page; T E Kidd; W D Dupont; J F Simpson; L W Rogers
Journal:  Hum Pathol       Date:  1991-12       Impact factor: 3.466

View more
  11 in total

Review 1.  Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer.

Authors:  Celeste M Nelson; Mina J Bissell
Journal:  Annu Rev Cell Dev Biol       Date:  2006       Impact factor: 13.827

2.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.

Authors:  A Maitra; I I Wistuba; C Washington; A K Virmani; R Ashfaq; S Milchgrub; A F Gazdar; J D Minna
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 3.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 4.  The enigmatic nature of apocrine breast lesions.

Authors:  P Zagorianakou; N Zagorianakou; D Stefanou; G Makrydimas; N J Agnantis
Journal:  Virchows Arch       Date:  2006-03-29       Impact factor: 4.064

Review 5.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

Review 6.  Putting tumours in context.

Authors:  M J Bissell; D Radisky
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

7.  The matricellular protein CCN6 differentially regulates mitochondrial metabolism in normal epithelium and in metaplastic breast carcinomas.

Authors:  Mai Tran; Shoshana A Leflein; Maria E Gonzalez; Celina G Kleer
Journal:  J Cell Commun Signal       Date:  2021-11-22       Impact factor: 5.908

8.  Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas.

Authors:  Pamela S Larson; Antonio de las Morenas; Sheila R Bennett; L Adrienne Cupples; Carol L Rosenberg
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

Review 10.  The tumor microenvironment is a dominant force in multidrug resistance.

Authors:  Ana Luísa Correia; Mina J Bissell
Journal:  Drug Resist Updat       Date:  2012-02-13       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.